These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27574437)

  • 21. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.
    Zografou I; Sampanis C; Gkaliagkousi E; Iliadis F; Papageorgiou A; Doukelis P; Vogiatzis K; Douma S
    Hormones (Athens); 2015; 14(1):118-25. PubMed ID: 25402372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
    Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
    Foley JE; Sreenan S
    Horm Metab Res; 2009 Dec; 41(12):905-9. PubMed ID: 19705345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Barnett AH
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
    Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Wang Y; Dunning BE; Foley JE
    Diabetes Obes Metab; 2008 Nov; 10(11):1114-24. PubMed ID: 18355325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.
    Gueler I; Mueller S; Helmschrott M; Oeing CU; Erbel C; Frankenstein L; Gleißner C; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA; Doesch AO
    Drug Des Devel Ther; 2013; 7():297-303. PubMed ID: 23630415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
    Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
    Schweizer A; Dejager S; Foley JE; Kothny W
    Vasc Health Risk Manag; 2011; 7():49-57. PubMed ID: 21415917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Strózik A; Stęposz A; Basiak M; Drożdż M; Okopień B
    Pharmacol Rep; 2015 Feb; 67(1):24-31. PubMed ID: 25560571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vildagliptin in the treatment of type 2 diabetes mellitus.
    Stamataros G; Schneider SH
    Expert Opin Pharmacother; 2011 Aug; 12(12):1967-73. PubMed ID: 21679097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.
    Dejager S; Schweizer A; Foley JE
    Vasc Health Risk Manag; 2012; 8():339-48. PubMed ID: 22661900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.